Nevertheless, this phenomenon is known to start early in course of the disease, and after a two-year duration from the onset, patients experience significant bone loss in the hip and spine in all locations; notably, many authors observed a remarkable, more severe reduction in BMD ACPA-positive early RA patients, suggesting a direct effect of autoantibodies in bone re-modelling [31]. The gene discussed is PRTN3; the disease is rheumatoid arthritis.